Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Parker-Hannifin Down Over 7%, On Track for Largest Percent Decrease Since April 2025 -- Data Talk

Parker-Hannifin Down Over 7%, On Track for Largest Percent Decrease Since April 2025 -- Data Talk

Dow JonesDow Jones2026/10/22 18:57

Parker-Hannifin Corporation (PH) is currently at $887.54, down $70.68 or 7.38%

--Would be lowest close since June 10, 2026, when it closed at $875.60

--On pace for largest percent decrease since April 3, 2025, when it fell 11.49%

--Currently down two of the past three days

--Down 7.1% month-to-date

--Up 0.98% year-to-date

--Down 17.35% from its all-time closing high of $1073.87 on Aug. 7, 2026

--Up 15.84% from 52 weeks ago (Oct. 23, 2025), when it closed at $766.20

--Down 17.35% from its 52-week closing high of $1073.87 on Aug. 7, 2026

--Up 15.84% from its 52-week closing low of $766.20 on Oct. 23, 2025

--Traded as low as $877.23; lowest intraday level since June 10, 2026, when it hit $875.60

--Down 8.45% at today's intraday low; largest intraday percent decrease since April 10, 2025, when it fell as much as 9.56%

All data as of 2:55:44 PM ET

Source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

October 22, 2026 14:57 ET (18:57 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Goldman Sachs comments on AMD (AMD.US) Q3 performance: Data center CPU and GPU show strong performance, growth visibility for 2027 is clear

Goldman Sachs released a research report maintaining a "Buy" rating on AMD (AMD.US) with a 12-month target price of $675.

智通财经•2026/11/04 03:53

AbbVie (ABBV.US) expands Oxford R&D facility in UK, betting on innovation in immunology, neuroscience, and oncology drugs

AbbVie announced on Wednesday that, as part of an investment plan exceeding 120 million pounds (approximately $161 million), the company has expanded its research and development facility in Oxford, United Kingdom.

智通财经•2026/11/04 02:51